Imetelstat improves patient-reported outcomes and quality of life in lower-risk myelodysplastic syndromes: results from the phase III IMerge study.

The imetelstat group showed a trend toward improvement in mean change from baseline across QUALMS Total and subscale scores at each cycle, while the placebo group showed minimal change ( Figure 3B ).

also in 53,322 other papers